safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
Published 2 years ago • 209 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
1:38
the efficacy of cevostamab in r/r multiple myeloma and the importance of bispecific antibodies
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
4:17
evaluating the safety and efficacy of elranatamab in multiple myeloma
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
6:17
myeloma made simple: bispecific antibodies made simple | bispecific antibodies for myeloma treatment
-
![single-cell immune profiling of whole blood with a 37-marker mass cytometry assay [webinar]](https://i.ytimg.com/vi/shcGDVz1_cM/mqdefault.jpg)
38:42
single-cell immune profiling of whole blood with a 37-marker mass cytometry assay [webinar]
-
4:36
haemonetics
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:12
magnetismm-1: investigating the efficacy of elranatamab in patients with r/r multiple myeloma
-
2:06
safety & efficacy of cevostamab in patients with heavily pre-treated r/r multiple myeloma
-
1:15
how bcma targeting bispecific antibodies may impact the subsequent use of car-t therapy in myeloma
-
1:22
risk of infection in patients with multiple myeloma treated with bispecific antibodies
-
1:37
the promise of elranatamab and other bispecifics in the treatment of myeloma
-
2:39
the safety and efficacy of hbi0101 for the treatment of r/r myeloma
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
2:32
the safety and efficacy of isatuximab for r/r myeloma: insights from icaria-mm, ikema & candor
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma